Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
ISX:DGNS's 14-Day RSI is ranked worse than 96.79% of 218
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.335
vs ISX:DGNS: 78.17
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
PT Diagnos Laboratorium Utama Tbk 14-Day RSI Related Terms
ISX:DGNS vs TMO, DHR, NTRA: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, PT Diagnos Laboratorium Utama Tbk's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Diagnos Laboratorium Utama Tbk 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Diagnos Laboratorium Utama Tbk's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where PT Diagnos Laboratorium Utama Tbk's 14-Day RSI falls into.
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) has a 14-Day RSI of 78.17 as of Sep. 07, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PT Diagnos Laboratorium Utama Tbk and its competitors. According to the industry distribution chart, PT Diagnos Laboratorium Utama Tbk ranks #211 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 96.8%.
Is PT Diagnos Laboratorium Utama Tbk's 14-Day RSI too high?
PT Diagnos Laboratorium Utama Tbk's current 14-Day RSI is 78.17. The Medical Diagnostics & Research industry median 14-Day RSI is 50.34. PT Diagnos Laboratorium Utama Tbk's value of 78.17 is 55.3% above this industry median. Based on the distribution chart, PT Diagnos Laboratorium Utama Tbk ranks #211 out of 218 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, PT Diagnos Laboratorium Utama Tbk has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does PT Diagnos Laboratorium Utama Tbk's 14-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Diagnos Laboratorium Utama Tbk ranks #211 out of 218 companies for 14-Day RSI. This places PT Diagnos Laboratorium Utama Tbk in the lower half of its industry. The industry median 14-Day RSI is 50.34. PT Diagnos Laboratorium Utama Tbk's value of 78.17 is 55.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 50.34, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Diagnos Laboratorium Utama Tbk's current 14-Day RSI of 78.17 is 55.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PT Diagnos Laboratorium Utama Tbk and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 50.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Diagnos Laboratorium Utama Tbk's current 14-Day RSI is 78.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diagnos Laboratorium Utama Tbk stock overvalued right now?
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) has a current 14-Day RSI of 78.17. The current 14-Day RSI is 78.17 and 55.3% above the Medical Diagnostics & Research industry median of 50.34. PT Diagnos Laboratorium Utama Tbk's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For PT Diagnos Laboratorium Utama Tbk (ISX:DGNS), the current 14-Day RSI is 78.17 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Diagnos Laboratorium Utama Tbk operates in the field of Health Support Services and Private Clinic Activities. It provides health support service activities managed by both the government and the private sector, such as health laboratories in the form of X-Ray Laboratories, and other diagnostic imaging centers, as well as blood testing, private clinics, pharmaceutical warehouses, eye banks, blood banks, sperm banks, organ transplant banks, and other medical support services. Its products and services include Clinical Pathology Laboratory, Anatomical Pathology Laboratory, Genomics Laboratory, Homecare Health Services, Corporate Health Services, Microbiology Laboratory, and Research Services.
18GF Score
Get the complete analysis for ISX:DGNS
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DGNS has been successfully added to your 
